Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Interferon-β-1b in multiple sclerosis - too costly?

    • 7 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Interferon-β-1b in multiple sclerosis - too costly?. Pharmacoecon. Outcomes News 105, 5 (1997). https://doi.org/10.1007/BF03271437

    Download citation

    Keywords

    • Public Health
    • Multiple Sclerosis
    • Health Outcome
    • Interferon
    • Adis International Limited